中药联合化疗治疗Ⅳ期不可手术胃癌的回顾性临床分析。

Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis.

机构信息

Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.

出版信息

J Integr Med. 2017 Nov;15(6):469-475. doi: 10.1016/S2095-4964(17)60377-7.

DOI:10.1016/S2095-4964(17)60377-7

PMID:29103417

Abstract

OBJECTIVE

Traditional Chinese medicine (TCM) is regarded as an important treatment for gastric cancer patients, especially for those in advanced stage. To evaluate the effects of TCM treatment on gastric cancer patients, the authors performed a retrospective study to report the result of the integrated treatment of TCM with chemotherapy for stage IV non-surgical gastric cancer.

METHODS

In this study, 182 patients with stage IV and non-surgical gastric cancer were retrospectively analyzed to evaluate the effects of TCM integrated with chemotherapy. Among the 182 cases, 88 cases received integrated therapy consisting of TCM and chemotherapy, while 94 cases received chemotherapy alone. The overall survival and Karnofsky performance status (KPS) score were measured as the main outcome.

RESULTS

The median overall survival of the integrated therapy group and chemotherapy group were 16.9 and 10.5 months, respectively. The 1-, 3- and 5-year survival rates of integrated therapy group vs. chemotherapy group were 70% vs. 32%, 18% vs. 4%, and 11% vs. 0%, respectively. There was a significant difference between the two groups (χ = 42.244, P > 0.001). After six-month treatment, KPS scores of the integrated therapy group and the chemotherapy group were 75.00 ± 14.78 and 60.64 ± 21.39, respectively (P > 0.001). The Cox regression analysis showed that TCM treatment is a protective factor for patients' overall survival.

CONCLUSION

This study demonstrated that TCM integrated with chemotherapy may prolong overall survival and improve survival rate and life quality of patients with stage IV non-surgical gastric cancer.

摘要

目的

中医（TCM）被认为是胃癌患者的重要治疗方法，尤其适用于晚期患者。为了评估 TCM 治疗对胃癌患者的影响，作者进行了一项回顾性研究，报告了 TCM 联合化疗治疗Ⅳ期不可手术胃癌的综合治疗结果。

方法

本研究回顾性分析了 182 例Ⅳ期不可手术胃癌患者，评估 TCM 联合化疗的疗效。182 例患者中，88 例接受 TCM 联合化疗综合治疗，94 例接受单纯化疗。主要观察终点为总生存期和卡氏功能状态评分（KPS）。

结果

综合治疗组和化疗组的中位总生存期分别为 16.9 个月和 10.5 个月。综合治疗组和化疗组的 1 年、3 年和 5 年生存率分别为 70%比 32%、18%比 4%、11%比 0%，两组比较差异有统计学意义（χ=42.244，P>0.001）。治疗 6 个月后，综合治疗组和化疗组的 KPS 评分分别为 75.00±14.78 和 60.64±21.39，两组比较差异有统计学意义（P>0.001）。Cox 回归分析显示，TCM 治疗是患者总生存期的保护因素。